Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael R Loken

Showing results (41-50 of 93) with videos related to

Pageof 10
Sort By:
Blood|January 18, 2007
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapyRoland B Walter, Ted A Gooley, Vincent H J van der Velden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2015
Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology GroupKatherine Tarlock, Todd A Alonzo, Robert B Gerbing, et al.
International Journal of Hematology|February 1, 2014
Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remissionSung-Chao Chu, Tso-Fu Wang, Yu-Chieh Su, et al.
Blood|June 1, 2012
Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology GroupMichael R Loken, Todd A Alonzo, Laura Pardo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2021
CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology GroupAdam J Lamble, Lisa Eidenschink Brodersen, Todd A Alonzo, et al.
American Journal of Clinical Pathology|September 27, 2012
Array-based karyotyping in plasma cell neoplasia after plasma cell enrichment increases detection of genomic aberrationsBarbara K Zehentner, Luise Hartmann, Krystal R Johnson, et al.
Clinical Chemistry|October 17, 2014
Detection of clonal evolution in hematopoietic malignancies by combining comparative genomic hybridization and single nucleotide polymorphism arraysLuise Hartmann, Christine F Stephenson, Stephanie R Verkamp, et al.
Cytometry. Part B, Clinical Cytometry|April 4, 2023
The impact of Down syndrome-specific non-malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual diseaseFan-Chi Hsu, Chad Hudson, Elisabeth R Wilson, et al.
Cancer|April 29, 2014
AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemiaTodd M Cooper, Todd A Alonzo, Robert B Gerbing, et al.
Cytometry. Part B, Clinical Cytometry|April 27, 2011
Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopeniasJevon A Cutler, Denise A Wells, Arjan A van de Loosdrecht, et al.
Pageof 10

Showing results (41-50 of 93) with videos related to

Sort By:
Pageof 10
Blood|January 18, 2007
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapyRoland B Walter, Ted A Gooley, Vincent H J van der Velden, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2015
Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology GroupKatherine Tarlock, Todd A Alonzo, Robert B Gerbing, et al.
International Journal of Hematology|February 1, 2014
Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remissionSung-Chao Chu, Tso-Fu Wang, Yu-Chieh Su, et al.
Blood|June 1, 2012
Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology GroupMichael R Loken, Todd A Alonzo, Laura Pardo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 2, 2021
CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology GroupAdam J Lamble, Lisa Eidenschink Brodersen, Todd A Alonzo, et al.
American Journal of Clinical Pathology|September 27, 2012
Array-based karyotyping in plasma cell neoplasia after plasma cell enrichment increases detection of genomic aberrationsBarbara K Zehentner, Luise Hartmann, Krystal R Johnson, et al.
Clinical Chemistry|October 17, 2014
Detection of clonal evolution in hematopoietic malignancies by combining comparative genomic hybridization and single nucleotide polymorphism arraysLuise Hartmann, Christine F Stephenson, Stephanie R Verkamp, et al.
Cytometry. Part B, Clinical Cytometry|April 4, 2023
The impact of Down syndrome-specific non-malignant hematopoietic regeneration in the bone marrow on the detection of leukemic measurable residual diseaseFan-Chi Hsu, Chad Hudson, Elisabeth R Wilson, et al.
Cancer|April 29, 2014
AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemiaTodd M Cooper, Todd A Alonzo, Robert B Gerbing, et al.
Cytometry. Part B, Clinical Cytometry|April 27, 2011
Phenotypic abnormalities strongly reflect genotype in patients with unexplained cytopeniasJevon A Cutler, Denise A Wells, Arjan A van de Loosdrecht, et al.
Pageof 10